1/3/2013

As NIH funding for biomedical research has dwindled, scientists are turning to big drugmakers and disease-focused foundations, shifting the focus from basic to translational research, writes Luke Timmerman. The result could be a slew of new drugs, devices and diagnostics over the next decade, he writes. But moving too far away from basic research could bring missed opportunities for "a whole series of bigger breakthroughs that can come only from asking basic, open-ended research questions about how genes, cells, and lower organisms work," he writes.

Full Story:
Xconomy

Related Summaries